Literature DB >> 30830848

Can Neutrophil to Lymphocyte Ratio Be a Predictor Tool for The Non-Sentinel Lymph Node Metastasis in Breast Cancer?

Atak Ibrahim, Yegen Fatih Serkan, Atak Tuba, Bagcivan Erol, Polat Lütfi.   

Abstract

Background: To investigate the relationship between neutrophil to lymphocyte ratio (NLR) and non-sentinel lymph node (SLN) metastasis in early stages of breast cancer.
Methods: Records of patients with clinically early stage (cT1-T3, N0) invasive breast cancer who underwent SLN biopsy in combination with blue dye and lymphoscintigraphy between April 2015 and January 2017 were noted retrospectively. Pre-treatment NLR of the patients with and without non-SLN metastasis were compared.
Results: A total of 178 patients with a mean age of 51,65+-10,93 years were included. NLR was statistically significant in the non-SLN positive patients (p=0.011). Lymphovascular invasion and extracapsular extension of SLN were more common in the non-SLN positive group (all p 0.05). The ODDS value was found to be 3,733 (95% CI: 1,05-13,24) and the risk of metastasis in those with lymphovascular invasion was 3.73 fold. The ODDS value was found to be 10,267 (95% CI: 2,63- 40,12) and the risk of metastasis was 10,267 times greater in those with capsule spread.
Conclusion: Lymphovascular invasion, extracapsular extension and NLR are the predictive parameters of non-SLN positivity. Pre-surgical NLR is a useful diagnostic tool for predicting non-SLN metastasis. Celsius.

Entities:  

Keywords:  breastcancer; neutrophiltolymphocyteratio; non-sentinellymphnode; sentinellymphnodemetastasis

Mesh:

Year:  2019        PMID: 30830848     DOI: 10.21614/chirurgia.114.1.83

Source DB:  PubMed          Journal:  Chirurgia (Bucur)        ISSN: 1221-9118


  1 in total

Review 1.  The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer.

Authors:  Li Chen; Xiangyi Kong; Chengrui Yan; Yi Fang; Jing Wang
Journal:  Onco Targets Ther       Date:  2020-02-14       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.